• Thursday, March 2, 2023 @ 12:00 am


Cosmo reported record preliminary 2022 results with key drivers such as Winlevi off to a solid start in the US. Legacy products such as Lialda, and Uceris/Cortiment added to the record revenues. Cosmo is one of the few profitable SIX-listed biopharma companies with sufficient cash to fund its development plans and pay dividends.

Key catalysts include:

1. Start phase III trial Breezula in male alopecia (Q1 2023)
2. Winlevi licensing agreements (2023)
3. Winlevi filing for EU approval (H2 2023)

To the full Cosmo Valuation Report

You may also be interested in